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ABSTRACT 
S-nitrosation is the attachment of a nitric oxide moiety to the thiol side chain of 
cysteine. S-nitrosoglutathione (GSNO) acts as a bioactive reservoir for NO to maintain an 
equilibrium in the concentration of NO in the body. Due to this, the study of the enzyme 
S-nitrosoglutathione reductase has of great interest because of its ability to metabolize 
GSNO. S-nitrosoglutathione reductase’s activity has been linked to a number of human 
diseases. Chapter 1 of this thesis presents a proposed allosteric binding domain on 
GSNOR. Positive cooperativity (sigmoidal deviation) was observed from steady state 
analysis of GSNOR which indicated an affinity for the binding of GSNO at this site. The 
presence of such a site was further supported by Molecular docking simulations and 
HDX-MS which showed that the amino acids Gly321, Lys323, Asn185 and Lys188 
interact with molecules bound at this site. 
Chapter two introduces four reagents that can function as probes or pseudo-
substrates for the monitoring of enzymatic activity as well as measuring concentrations of 
free thiols in vitro and live cells. These reagents are N,N-di(thioamido-fluoresceinyl)-
cystine (DTFCys2), N,N-di(thioamido-fluoresceinyl)-homocystine (DTFHCys2), N-
amido-O-aminobenzoyl-S-nitrosoglutathione (AOASNOG), and N-thioamido-
fluoresceinyl-S-nitroso-glutathione (TFSNOG). They are easy to prepare and purity and 
can be used in various applications. 
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CHAPTER 1 
 
Proposed Allosteric site on S-nitrosoglutathione Reductase 
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Chapter summary 
 S-nitrosoglutathione reductase, an enzyme in the alcohol dehydrogenase family, is 
responsible for the metabolism of GSNO as well as the detoxification of formaldehyde in 
the body. Steady state assay of the WT of this enzyme revealed a deviation from the 
classical Michaelis Menten kinetics, fitting more into a sigmoidal curve. This led to the 
hypothesis that the enzyme has an allosteric site that binds the substrate GSNO and 
increases the activity of the enzyme. Molecular docking was used to visualize the 
possible location of such a site, and it was found adjacent to the structural zinc. Four 
amino acid residues were implicated to have an interaction with the substrate bound at the 
site. They are Lys188, Lys323, Asn185 and Gly321. Mutations to the Lysine residues 
were performed to monitor how the changes to the environment around this site would 
affect the activity of the enzyme and its affinity for binding the substrate. To further 
confirm the presence of the proposed allosteric site Hydrogen Deuterium exchange mass 
spectroscopy was performed. This exchange showed decreased uptake of deuterium by 
three of the four residues at the proposed site identified on the peptide list. Asn185 was 
not identified and will be part of the further investigations with respect to this 
experiment. All results obtained from the steady state analysis and HDX-MS support the 
hypothesis that there is an allosteric site on the enzyme GSNOR located adjacent to the 
structural zinc. 
 
 
 
 
 
 
 
3 
1.1 Nitric Oxide 
 
Nitric Oxide (NO) is a diatomic free radical gasotransmitter. It is the first 
identified gasotransmitter discovered to be the endothelium-derived relaxing factor 
(EDRF) that is responsible for vascular smooth muscle relaxation. 1-4 NO is a well-
established signaling molecule involved in many physiological processes. These include 
the control of vascular tone and blood pressure, promoting angiogenesis, mediating 
neurotransmission, immune response, and wound healing.5 NO is also involved in the 
regulation of growth, immunity, environmental and root development of Plants.6 
1.1.1 NO Synthases 
NO regulation involves the control of nitric oxide synthases (NOS), a group of 
enzymes responsible for the biosynthesis of NO. Endogenous NO is enzymatically 
synthesized in mammalian tissues by three isoforms of NOS. These isoforms are 
neuronal NOS (nNOS, NOS 1), inducible NOS (iNOS, NOS 2) and endothelial NOS 
(eNOS, NOS 3) according to basal level of activity and constitutive expression in tissues. 
NOSs produce NO in eukaryotic cells which are found in animals, and some algae. Other 
organisms utilize alternative methods such as nitrite reduction in the production of NO.7-8 
The isoforms of NOS function as homodimers, catalyzing the oxidation of L-
arginine to L-citrulline and NO in the presence of molecular oxygen with reduced 
nicotinamide adenine dinucleotide phosphate (NADPH), as a co-substrate.9-10 NO 
productions catalyzed by NOS require a number of cofactors/coenzymes such as flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), tetrahydrobiopterin (BH4) 
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and calmodulin. 11 nNOS is natively expressed in the neurons of the peripheral and 
central nervous system, in addition to the epithelial cells of various organs.12 nNOS 
activity is Ca2+ dependent and NO derived by nNOS mediates synaptic plasticity 
affecting complex physiological functions 13-14 and is a part of the central regulation of 
blood pressure.15-16 iNOS is expressed in the presence of inducing stimulants like 
cytokines. Once induced, it produces substantial amounts of NO and is completely Ca2+ 
independent. iNOS was discovered in macrophages and is involved in the immune 
system and inflammatory bowel disease (IBSs).17-18 eNOS from the name is expressed in 
the endothelial cells and just like nNOS is Ca2+ dependent. NO produced by this isoform 
results in vasorelaxation and protects blood vessels from thrombosis by the inhibition of 
platelet adhesion and aggregation.19-21 
1.1.2 NO signaling Mechanism   
There are several NO signaling mechanisms that have been identified. The most common 
are the classical, nonclassical and less classical mechanisms.22 Classical signaling 
involves the activation of soluble guanylate cyclase which then converts guanosine 
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). This leads to the 
activation of cGMP-dependent protein kinases subsequently facilitating down-stream 
effects. Nonclassical signaling suggests the formation of NO-induced posttranslational 
modifications (PTMs) such as S-glutathionylation, S-nitrosation and tyrosine nitration. 
The less classical signaling has important implication for cell respiration and intermediate 
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metabolism due to the interaction between NO and the mitochondrial cytochrome c 
oxidase.23-26 
 
1.2 Protein S-nitrosation 
S-nitrosation is the covalent attachment of a nitric oxide (NO) group to the thiol 
side chain of the amino acid cysteine resulting in the formation of S-nitrosothiols 
(SNOs).27 The post-translational modification of Cysteine residues in proteins has 
been regarded as a primary mechanism which NO uses to regulate cell signaling.28-30 
S-nitrosation of proteins is not directly catalyzed by enzymes, however protein 
catalyzed S-nitrosation and denitrosation pathways have been discovered and are yet 
to be understood in the context of global proteomic analysis.29 There has been 
increasing evidence that suggests the participation of S-nitrosation in both normal 
physiology and pathogenesis of several human diseases.31 For instance, in GSNOR 
knockout mice increased levels of SNO-proteins were observed which demonstrates 
the role of GSNO/GSNOR in SNO-protein homeostasis. First step in S-nitrosation 
process is NO oxidized to higher oxides of nitrogen such as dinitrogen trioxide 
(N2O3) when reacted with molecular oxygen (O2). N2O3 can react directly with the 
thiols as shown in equation 1.2.1. 
                                                                                                                             RS- + N2O3                     RSNO +NO2-                          Equation 1.2.1 
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A proposed alternative mechanism for the formation of SNO is the reacting of NO 
with reduced thiol forming a radical intermediate.31 Recent evidence shows that the 
reaction of NO with molecular oxygen (O2) is not only a primary pathway for S-
nitrosation of thiols but might also yield products of thiol oxidation sometimes greater 
than RSNOs.30,32                      
S-nitrosation of proteins occurs through transnitrosation. Transnitrosation 
reactions are all fully reversible and often include SNOs of low molecular weight 
such as GSNO.29,33 
                                                                                                                             
S-nitrosylation is involved in the physiology and dysfunction of cardiac, airway and 
skeletal muscle as well as the immune system showing wide-ranging functions in cell 
and tissues.34-37  
1.3 S-nitrosoglutathione Reductase (GSNOR) 
1.3.1 GSNOR as a product of ADH 5 
S-nitrosoglutathione Reductase (GSNOR) is an enzyme in the alcohol 
dehydrogenase (ADH) family. The alcohol dehydrogenase family has been evolutionarily 
conserved from bacteria to man with five distinct classes containing seven known 
isoforms.38 ADH is involved in several important roles in the body but the most studied is 
the metabolism of short chain alcohols. GSNOR is a member of the class III alcohol 
Protein-S- + GSNO          Protein-SNO + GS-          Equation 1.2.2 
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dehydrogenase family. GSNOR is encoded by the ADH5 gene located on the reverse 
strand of chromosome 4 (4q23-Chr4: 99,993,567-10,000,985).38  
GSNOR also known as ADH5, FALDH, GSH-FDH and Formaldehyde 
dehydrogenase is a ubiquitously expressed NADH dependent enzyme with the ability to 
oxidize medium-chain alcohols and the GSH adduct S-hydroxymethylglutathione 
(HMGSH). It also reduces GSNO using NADH as a cofactor producing GSNHOH as an 
intermediate which can further react with GSH to produce GSSG and NH2OH. GSNOR 
when acting as a glutathione-dependent formaldehyde dehydrogenase is critical in the 
metabolic elimination of formaldehyde (Figure 1.3.1). This formaldehyde is eliminated 
by reacting with glutathione to produce the adduct S-hydroxymethylglutathione which 
can then be oxidized to S-formylglutathione. This reaction requires NAD+ as a cofactor 
which leads to the production of NADH, a cofactor necessary for the metabolism of 
GSNO.39-41 GSNOR in plants is important for growth and root development. Most of the 
studies on GSNOR done on plant are mainly focused on the Arabidopsis thaliana plant 
however, there have been papers published on sunflower (Helianthus annuus L.), pepper 
(Capsicum annuum L.), maize and rice.42 GSNOR in humans can be found in the 
endometrium, ovary, fat, esophagus, prostate, liver and kidney.43  
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Figure 1.3.1: GSNORs role in the detoxification of formaldehyde. In step 1, glutathione reacts with a 
formaldehyde at the free thiol group to produce the spontaneous adduct HMGSH. In step 2, HMGSH is 
oxidized at the S-hydroxymethyl group by GSNOR to S-formylglutathione using NAD+ as a cofactor. 
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1.3.2. GSNOR protein structure 
GSNOR functions as a homodimer with 40kDa subunits containing 347 amino 
acids per subunit (Figure 1.3.2, page 11). In each subunit there is a catalytic domain and a 
coenzyme binding domain. GSNOR is a metalloprotein with two zinc atoms per 
monomer for a total of four zinc atoms per functional enzyme. The zinc atoms are both in 
the catalytic domain however the catalytic zinc acts as a lewis acid during catalysis while 
the structural zinc is critical for the maintenance of proper protein structure. GSNOR 
requires a coenzyme that may vary depending on the substrate. These include NADH, 
NADPH+H+ and, NAD(P)+.44   
The amino acid residues involved in the binding of substrates are highly 
conserved, particularly Glu68 and Arg379 as they are integral to the catalysis 
mechanism.45,46 The catalytic zinc is coordinated by the residues Cys45, His67, Cys174 
and Glu68 or a water molecule. Similarly, the structural zinc is coordinated by four 
closely spaced cysteine residues Cys97, Cys100, Cys103 and Cys111.47,48 Although the 
structural zinc is not involved in the catalytic mechanism mutations to any of the cysteine 
residues results in the enzymes inactivity. The catalytic domain moves towards the 
coenzyme binding domain during the formation of the complex HMGSH with NADH 
present. 
We hypothesize the presence of an allosteric site on GSNOR that binds the 
substrate GSNO and enhances the activity of the enzyme. This site is postulated to be 
localized in a cleft adjacent to the structural zinc atom. Four amino acid residues in this 
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local with molecules bound at this site. The amino acid residues involved are Lys323, 
Gly321, Asn185 and Lys188 with both Lysine residues proposed to interact indirectly 
with molecules while the Glycine and Asparagine residues interact directly with bound 
molecules. This was Supported by molecular docking (MD) simulations performed on the 
enzyme and the substrate GSNO. 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Figure 1.3.2 GSNOR crystal structure showing the 40kDa subunits. (A) the enzyme structure showing the 
four zinc atoms. The active site is located in the cleft between the catalytic zinc and the structural zinc. (B) 
shows the catalytic zinc coordinated by two of the three Cysteine residues and the Histidine. (C) shows the 
structural zinc coordinated by the four Cysteine residue in close proximity of each other were two of the 
residues make up the CXXC motif of the Enzyme. 
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1.3.3. Functions of GSNOR 
GSNOR as previously mentioned is highly conserved in eukaryotic and 
prokaryotic organisms and expressed in all tissues studied.49,50 Multiple studies have 
provided documentation of the involvement of GSNOR in a number of pathways from 
metabolism of GSNO,51-55 to w-hydroxy fatty acid oxidation,56,57 and formaldehyde 
detoxification.58-61 The most characterized and studied functions of GSNOR are the 
glutathione-dependent formaldehyde oxidation and the NADH-dependent GSNO 
reduction (fig 1.3.1 and fig 1.3.3). The glutathione-dependent formaldehyde 
dehydrogenase activity is important for the elimination of formaldehyde, a classified 
carcinogen because of its high reactivity with DNA and proteins.62 Studies have shown 
that GSNOR is localized in the cytoplasm and as a condensed chromatin in the nucleus,63 
this supports its function in the elimination of formaldehyde and protecting DNA from its 
toxicity.  
The substrates that are preferred by GSNOR are HMGSH and GSNO. However, 
GSNO is considered the best substrate due to its catalytic efficiency of metabolism being 
twice that of HMGSH.64 GSNO is metabolized by the reductase activity of GSNOR with 
the first step being the reduction of GSNO in the presence of the NADH to the unstable 
intermediate glutathione N-hydroxysulfenamide (GSNHOH). In the presence of excess 
GSH in the system, GSNHOH will react with the GSH to produce a glutathione dimer 
(GSSG) and a side product of Hydroxylamine (NH2OH) (Figure 1.3.3). When no GSH is 
present the reaction can go in a different direction with GSNHOH spontaneously forming 
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glutathione sulfonamide (GSNONH2) which can then be hydrolyzed under acidic 
conditions to glutathione sulfonic acid (GSOOH) and ammonia (NH4+). The above 
reaction schemes are all irreversible.  
Under physiological conditions, the ratio of NADH/NAD+ present is typically 
low.65 This is not favorable for reductive pathways that require NADH implying that the 
reductase activity of GSNOR may depend on the availability of the cofactor. An increase 
in cellular NADH levels can be triggered by various factors like the inhibition of NADH 
dehydrogenase.66 GSNOR deficient mice exhibit substantial increases in protein s-
nitrosation.67 In the cellular environment GSNO is observed to be in equilibrium with S-
nitrosated proteins via reversible transnitrosation, while the observation of increased 
levels of S-nitrosation places GSNOR in a crucial role for the maintenance of SNO 
homeostasis by reducing GSNO. 
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Figure 1.3.3 Reaction scheme showing how GSNOR works. (A) shows the process by which the substrate 
GSNO is metabolized by the enzyme GSNOR in the presence of the cofactor NADH to the unstable 
intermediate GSNHOH. (B) GSNHOH in the presence of excess GSH will react further to produce GSSG. 
(C) When there is no GSH present GSNHOH spontaneous produces GSONH2 which can be further 
hydrolyzed to produce Glutathione sulfuric acid and Ammonia 
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1.3.4. Physiology and Inhibitors of GSNOR  
GSNOR plays a crucial role in the variation of NO in the cells. NO is highly 
reactive and will form stable RSNO equilibrium in the presence of GSH in the form of 
GSNO, a reservoir of bioavailable NO. NO and by extension GSNO plays a critical role 
in the relaxation of smooth muscle,68-70 cardiopulmonary regulation71-73, and several other 
intra/extracellular functions.74 GSNOR dysregulation has been implicated in numerous 
diseases such as asthma, cystic fibrosis and intestinal lung disease. GSNOR knockout 
mice have been used to obtain valuable data related to GSNOR function. Canonical NO-
mediated pathways and RSNO levels are severely modified when GSNOR activity is 
modulated. GSNOR plays an important protective role in the immune system’s 
development of lymphocytes. GSNOR knockout mice show a decrease in CD4 
thymocyte development and an increase in lymphocytic apoptosis.75 GSNOR’s regulation 
activity in the brain affects a broad swath of cellular functions ranging from neural 
development to other neurodegenerative diseases seen in adults. 
GSNO has been identified as a long-lived and potent relaxant of human airway 
in pulmonary physiology, due to its role as a reservoir for NO. This is characterized by 
inflammation and hyper-responsiveness in the airway.76 GSNO has been linked to other 
diseases like IBS, autoimmune encephalomyelitis and more. An increase in SNO levels in 
knockout mice with asthma lead to the study of therapeutic approaches for the inhibition 
of GSNOR activity to restore SNO levels. Investigations into inhibitors of GSNOR are 
on-going to aid patients affected by some of the diseases. The most productive progress 
 
 
 
 
 
16 
in the regulation of GSNOR is the development of N9115, an inhibitor marketed as 
Cavosonstat, that assists cystic fibrosis (CF) patients with the DF508-CFTR mutation. 
This mutation occurs within the gene for the cystic fibrosis transmembrane conductance 
regulator (CFTR) and accounts for most of cases of CF.77,78 N91115 ensures the 
availability of GSNO to promote CFTR development and plasma membrane stability via 
its inhibition of GSNOR.  
1.4 Computational study of the proposed allosteric site   
A computational study of the enzyme to identify the location of the proposed 
allosteric site via the measurement of minimum energy between the substrate and the 
enzyme was conducted using molecular docking simulations. This study was done as a 
collaboration between Sahar Nikoo, Dr. James Gauld, Dr. Bei Sun, and Dr. Bulent 
Mutus. The crystal structure for GSNOR utilized was obtained from the PDB library 
(ID:3QJ5) and was loaded onto the Molecular Environment Software (MOE). This study 
revealed that at the speculated site, the bound ligand interacts with four amino acid 
residues. These are lysine188, lysine323, glycine321 and asparagine185 (Figure 1.4). The 
docking results showed that when GSNO is bound at the proposed site, it interacts 
directly with the residues Gly321 and Asn185. The results also show that Lys188 and 
Lys323 interact with GSNO via a solvent network of hydrogen bonds.5 Docking scores 
obtained from this study show a score of -8.60 when GSNO is bound to the known active 
site of the enzyme and a score of -10.4 when GSNO binds to the postulated allosteric site. 
Docking scores are used to predict the binding affinity of a molecule with a low score 
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showing the system is stable and shows the interaction is favorable. This study further 
confirms the presence of the proposed allosteric binding site for the substrate GSNO. 
 
 
Figure 1.4 Molecular docking simulation showing the location of the proposed allosteric site and how 
when GSNO is bound it interacts with the implicated residues direct or via the solvent network of hydrogen 
bonds. The interactions via hydrogen bonds are shown by the blue lines. 
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1.5 Hydrogen deuterium exchange (HDX) MS 
A Hydrogen deuterium exchange experiment was carried out using a Synapt G1 
that was properly fitted with custom TRESI apparatus as per Wilson et al.53 The reagents 
used for this are reported in appendix B from the work done by Kathleen Fontana. The 
experiment was performed using 5- and 10-mm reaction spaces corresponding to 2 and 4 
seconds, respectively. Data collection was done in IMS mode within the range of 400-
1500 m/z. Experimental uptake of deuterium for each peptide was calculated using a 
software that was custom-built for this purpose. Data was collected on the same day for 
all trials. These include 5-minute spectrums of GSNOR without deuterium exchange, 
with two- and four-seconds exchanges. This was followed by 5 min spectrums of 
GSNOR + 20x GSNO (excess) with the same conditions as mentioned above. 
1.5.1 (HDX) MS Results 
The results from the HDX experiments seen in Appendix B supports the presence 
of the proposed allosteric binding site. The incorporation of deuterium shows a shift in 
the distribution of peaks due to the addition of the heavier isotope. This shift 
corresponded to the amount of deuterium being acquired by the peptide. 20x GSNO was 
used to ensure the availability of the substrate in the reaction to enable easy observation 
of the interaction with the active site and the proposed allosteric site. Three of the four 
amino acid residues that were implicated to be involved in the interaction at the proposed 
site by computational studies are represented by the identified peptide list (appendix B). 
They are Lys188, Lys323 and Gly321.The results from the two- and four- seconds 
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experiment showed that most of the peptides had an increase in the uptake of deuterium 
and is summarized in Table 1.5.1. All other relevant results are in appendix B. 
 
Table 1.5.1 Change in Deuterium uptake by the residues implicated in allosteric binding. 
 
 
The Gly321, Lys188 and Lys323 residues that are associated with the allosteric site 
were identified by peptide MS-MS. These residues as well as those that surround the 
GSNO molecule from the computational study all showed a decrease in the uptake of 
deuterium. Lys323 showed the highest rate of decrease at 1.4%, Lys188 a decrease of 
0.4% and Gly321 which was represented twice on the peptide list showed decreases of 
0.9% and 1.4%. Peptides leading to the active site pocket as well as those involved in the 
binding of NADH and the catalytic zinc also showed a decrease in the uptake of 
deuterium. The 2 second exchange provided changes in peptide within the ranges of -
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1.8% to + 3.4% and -5.2% to +5.1% for deuterium uptake, respectively. These results 
support the presence of the allosteric site on the enzyme GSNOR as proposed. 
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1.6 Method and Materials 
1.6.1 GSNOR WT cloning and Protein isolation 
The ADH5 cDNA used for this project was initially cloned by Dr. Bei Sun, who also 
performed mutagenesis on said gene that resulted in the recombinant GSNOR with 6x-
histidine tags at each terminus as outline in appendix A. The pET28b_ADH5 was then 
transformed into BL21(DE3) E.coli cells to facilitate purification of the enzyme. 
 Protein purification begins with a single colony from the transformed BL21 cells 
grown on LB Kanamycin agar plates. The colony is grown in a sterile polypropylene 
culture tube containing 4ml of 2x YT media with 50 µg/ml of Kanamycin. The culture 
tubes are left to grow overnight at 37ºC while shaking for further use in growing a starter 
culture at a rate of 1ml of colony per 100ml of media under the same conditions. The 
starter culture is used to inoculate 1.5L of 2x YT media containing 50 µg/ml of 
Kanamycin and grown at 37 ºC until an optical density of 0.5-0.6 is reached. At this 
point, GSNOR expression is induced by the addition of IPTG to a final concentration of 
0.4mM. The induced culture was left for 24 hours at room temperature with shaking to 
incubate. The cells were then collected by centrifugation at 6000rpm, 4ºC for 30 minutes. 
The supernatant was discarded, and the pellet resuspended with lysis buffer, composed of 
50mM Tris-HCl, 150mM NaCl, 15mM imidazole, 1mM DTT, 1mM PMSF, 1% Triton 
X-100, 75µg/ml DNase I and 100µg/ml Lysozyme at pH8. The lysate was incubated on 
ice for 30mins and further lysed by pulse sonification (20 seconds on and 20 seconds off 
for a total of 8 pulses). Another round of centrifugation at 12000rpm,4ºC for 30mins was 
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performed and the supernatant further purified using a HIS-select Nickel Affinity Gel 
from Sigma-Aldrich (P6611). 
The Nickel column was equilibrated with a wash buffer (with no imidazole) and 
Affinity purification was performed by following the manufacturer’s protocol published 
by Sigma with modifications to buffer compositions. The wash buffer was composed of 
50mM Tris-HCl, 150mM NaCl and 40mM imidazole, while the elution buffer was 
composed of 50mM Tris-HCl, 150mM NaCl and 300mM imidazole both at pH 8. The 
eluted protein was then buffer exchanged into a storage solution at pH 7.4, composed of 
58mM Na2HPO4, 17mM of na2H2PO4, 68mM NaCl and 15% glycerol, using Amicon 
centrifugal 30,000 NMWL filter (Millipore sigma UFC 903008) and stored at -80ºC. 
 
 
1.6.2 GSNO synthesis 
Reduced glutathione was dissolved in a solution of cold water and 2 M HCl. An 
equal amount of sodium nitrite was added, and the reaction mixture was stirred at 4ºC in 
the dark for 40 minutes. GSNO was then precipitated using 10 mL of cold acetone and 
the final pink product was washed with cold water and cold acetone before it was 
lyophilized for storage at -20ºC. All steps followed as per Hart’s method.80 The final 
product was verified by obtaining absorbance readings at 335 nm. 
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1.6.3 GSNOR Kinetics 
Steady state analysis was performed on GSNOR WT and three mutants by varying 
GSNO as the substrate while keeping enzyme and NADH constant. A stock solution of 
20mM NADH was prepared using milli-Q water. GSNO stock solutions of 1mM and 
10mM were freshly prepared for each experiment using PBS buffer. GSNO of increasing 
concentration was added to a cuvette containing 80µM of NADH and PBS to a final 
reaction volume of 500µl. The reaction was initiated by the addition of 2µg of enzyme. 
The consumption of NADH during the reaction was monitored using the decrease in 
absorbance at 340nm over a period of 60 seconds using the Agilent 8453 UV/Vis 
spectrophotometer. The rate of the initial linear decrease corresponding to NADH uptake 
was plotted in correlation to the concentration of GSNO. From this, KM, Vmax and 
Catalytic efficiency kcat were calculated. 
 
 
 
 
 
 
 
 
 
 
24 
1.7 Results 
Steady state analysis of GSNOR WT revealed a sigmoidal deviation [Figure 1.7.1 
(i)] resulting in positive cooperativity. This led to the proposal of a possible allosteric site 
on the enzyme. Molecular docking simulations were performed to further investigate the 
presence of the allosteric binding site for the substrate GSNO. Hydrogen-Deuterium 
exchange experiments were also performed by Kathleen Fontana to investigate direct 
ligand interactions as per appendix B. 
 
 
1.7.1 GSNOR Kinetics  
Steady state kinetic assays of the WT were performed with the concentrations of 
NADH and enzyme kept constant while the concentration of GSNO was varied from 
0uM to 700uM. Upon analysis of experimental data obtained, the apparent KM, and Vmax 
were calculated and are summarized in Table 1.5.1. The Hill coefficient was used to 
quantitatively determine the cooperativity of ligand binding. The Hill constant observed 
was 1.61 ±	0.14. Mutations at the proposed allosteric binding site were used to observe 
changes in the rate of ligand binding and how important the Lysine residues are for 
binding. Lysine (K) residues at position 188 and 323 were mutated to alanine (A). Three 
mutants were studied; a double mutant and single mutants at each position. For each 
mutant KM, Vmax were determined. Hill constant (n) obtained from the data set are 
summarized in table 1.5.1. From the Hill constant obtained, it was inferred that the 
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enzyme was displayed positive cooperativity for the WT while the mutant K188A loses 
the sigmoidal activity. Negative cooperativity can be seen for the mutants K323A and 
K188/323A. This shows that both WT and K188A have an affinity for the ligand to bind 
at this site however once the mutation at the other position as well as the double mutation 
occurs all ligand binding affinity was lost. 
 
 
 
Table 1.7.1: Summary of experimental data obtained for the KM, Vmax, Hill constant, Kcat and the 
catalytic efficiency of GSNOR WT and three mutants 
 WT K188A K323A K188/323A 
KM (µM) 22.01 ± 3.8 28.51 ± 4.7 N/D N/D 
Vmax (µM/s) 0.0058 ± 0.0003 0.0052 ± 0.0003 0.0012 ± 0.0003 0.0019 ± 0.0001 
Hill constant (n) 1.61 ± 0.14 0.9 ± 0.085 0.1 ± 0.014 0.34 ± 0.21 
Kcat (s-1) 58,000 52,000 12,000 19,000 
Kcat/KM (s-1µM-1) 2,624 1,824 N/D N/D 
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Figure 1.7.1 (i) Plots of the kinetic data obtained for GSNOR WT and GSNOR K188A. The left panel shows 
the full Michaelis Menten plots (blue line) as well as the sigmoidal curve (red line) however the deviation 
cannot be seen. The right panel shows a zoom in plot at the lower concentrations, this shows the deviations 
from the classical Michaelis Menten plot. 
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Figure 1.7.1.ii Plots of the kinetic data obtained for GSNOR K323A and GSNOR K188/323A. The left 
panel shows the full Michaelis Menten plots (blue line) as well as the sigmoidal curve (red line) however 
the deviation cannot be seen. The right panel shows a zoom in plot at the lower concentrations, this shows 
the deviations from the classical Michaelis Menten plot. 
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1.8 Discussion 
The data obtained from the computational, steady state kinetics and HDX-MS studies 
of GSNOR support the hypothesis that there is indeed an allosteric site for the binding of 
the substrate GSNO present on the enzyme GSNOR. 
The steady state assay first performed on GSNOR WT showed a slight deviation 
from the Michalis Menten plot when a Hill constant was applied to fit a sigmoidal curve 
which led to the hypothesis of the presence of the proposed allosteric site and the desire 
to study it. In an attempt to understand how the presence of an allosteric site affects 
enzyme function, mutational study was done. 
The steady state assay performed gave results that show difference in KM, Vmax, and 
Hill constant. As table 1.5.1 shows the WT and mutant K188A show KM values that are 
close to the literature value of 27µM81 while the KM values of K323A and K188/323A 
decreases drastically. This shows that the mutations occurring at these sites lead to an 
almost complete loss in affinity for substrate binding that could be because of 
conformational changes in the enzyme structure. This was further confirmed by the Hill 
constant which showed positive cooperativity for the WT, non-cooperativity for the 
mutant K188A and negative cooperativity for the other mutants. The graphs show a slow 
rate moving towards the KM but a much faster rate on its way to the Vmax. The steady 
state data shows that although the computational study suggests that Lys323 does not 
interact directly with the substrate, the almost complete loss of activity after mutation 
suggests otherwise. 
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These results show that the activity of GSNOR is hyper-sensitive to structural 
changes at this other-than the active site. This is favorable for pharmaceutical companies 
that have been investigating the inhibition of this enzyme for treating diseases affiliated 
with the enzyme. This discovery could aid the company in designing small molecules that 
can attack the lysine residue at position 323 for instance. 
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1.9 Conclusion 
The results obtained from (1) the steady state assay with a Hill constant of 1.61±0.14 
for GSNOR WT and decreasing Hill constant for the mutants; (2) the results from the 
HDX-MS which showed a decrease in deuterium uptake of 1.4%, 0.4%, 0.9% and 1.4% 
for Lys323, Lys188, and (3) the two Gly321 peptides identified from the reaction of 
GSNOR and excess GSNO reaction; support the hypothesis that the enzyme GSNOR has 
an allosteric site present that binds the substrate GSNO, increases its rate of reaction, and 
is more fitted to the sigmoidal curve plot than the classical Michalis Menten. This site 
could be a potential target for pharmaceutical company in developing molecules that can 
disrupt GSNOR’s activity by attacking there. 
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1.10 Future direction 
To confirm the location and presence of an allosteric site, several steps may be taken 
in future experiments. First the mutation of the Lysine residue to another residue similar 
in size and charge to determine if the loss of the charge or the bulk side chain plays a role 
in the loss of affinity for the substrate. In addition, more HDX-MS trials should be 
performed to provide further confirmation. 
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CHAPTER 2 
Development of fluorogenic pseudo-substrates 
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Chapter Summary 
 This chapter describes the theoretical basis and the methods employed in 
synthesizing and characterizing four fluorogenic probes/pseudo substrates. The four 
probes synthesized are N,N-di(thioamido-fluoresceinyl)-cystine (DTFCys2), N,N-
di(thioamido-fluoresceinyl)-homocystine (DTFHCys2), N-amido-O-aminobenzoyl-S-
nitrosoglutathione (AOASNOG), and N-thioamido-fluoresceinyl-S-nitroso-glutathione 
(TFSNOG). These probes can be used in measuring and imaging free thiols present on 
cell surfaces, as substrates for the thiol reductase and S-nitrosothiol denitrosylase 
activities of the protein disulfide isomerase (PDI). It can also be used as a substrate for 
the S-nitrosothiol reductase activity of GSNOR in vitro and on live cells. 
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2.1 Fluorescence: A brief introduction 
 Fluorescence is a luminescence process involving susceptible molecules that emit 
light from electronically excited states made by either a physical or chemical mechanism. 
Fluorescence occurs by the absorption of photons in a singlet ground state to a singlet 
excited state. As the excited molecule returns to the ground state, it emits a photon of 
lower energy that corresponds to a longer wavelength than the absorbed photon. The 
energy loss is due to vibrational relaxation while in the excited state. Fluorescent bands 
center at wavelengths longer this shift towards the longer wavelengths is known as the 
stokes shift.82 Excited states are short-lived with a lifetime at about 10-8 seconds. 
Substance luminescence is affected by the molecular structure and the chemical 
environment. The molecular structure and chemical environment also determine the 
intensity of emission when luminescence does occur. In general molecules that can 
fluoresce are conjugated systems and the specific frequencies of excitation and emission 
are dependent on the molecule or atom. 
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Figure 2.1 Jablonski diagram of absorbance, non-radiative decay and fluorescence. 
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2.2 Fluorescein 
 The fluorescein dye is the most commonly used fluorescent probe due to its high 
molar absorptivity at a wavelength 494nm, making it a very useful and sensitive 
fluorescent label. Fluorescein is commercially available in many derivatives, the major 
one been Fluorescein isothiocyanate. Fluorescein isothiocyanate (FITC) is simply the 
original fluorescein molecule that was functionalized with an isothiocyanate reactive 
group which replace a hydrogen atom on the bottom ring of the structure. FITC is often 
used in cellular biology to label and track cells in fluorescence microscopy applications. 
FITC reacts readily with nucleophiles such as the amine and sulfhydryl groups of 
proteins. Many moieties can be conjugated with FITC making them useful in a wide 
variety of experimental procedures from immunofluorescence, Apoptosis detection, 
Nucleotide labelling, to in situ hybridization and many more.83 
 
 
Figure 2.2 A shows the fluorescein molecule, B shows the dianion form of fluorescein which give the best 
intensity of fluorescence and C shows the functionalized fluorescein molecule, the Fluorescein 
isothiocyanate derivative 
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2.3 The redox probes 
 The highlighted reagents would theoretically act as probes and pseudo substrates 
for several reactions. Three of such reactions are the enzyme catalyzed disulfide 
reduction (Equation 2.3.1), S-nitrosothiol denitrosylation by the release of NO or HNO 
(Equation 2.3.2) and the reduction of NO+ to NH2OH (Equation 2.3.3). 
 
 
 
 The four probes are fluorogenic, therefore when they partake in thiol redox 
reactions an increase in their fluorescence can be observed. The probes are N,N-
di(thioamido-fluoresceinyl)-cystine (DTFCys2, figure 2.3A), N,N-di(thioamido-
fluoresceinyl)-homocystine (DTFHCys2, figure 2.3B), N-amido-O-aminobenzoyl-S-
nitrosoglutathione (AOASNOG, figure 2.3D), and N-thioamido-fluoresceinyl-S-nitroso-
glutathione (TFSNOG, figure 2.3C). Intra-molecular quenching in these probes account 
for their low fluorescence when they are not a part of a reaction. Quenching in DTFCys2 
is due to the proximity of the two fluorophores to each as a result of structural stability 
via intramolecular H-bonding. The self-quenching is results from the collisional energy 
transfer that leads to thermalization of the electronic excitation energy. Fluorescence 
quenching in AOASNOG and TFSNOG occurs due to the overlap in spectrum of the 
functional group, S-N=O (lmax = 312nm and 545nm) with either the excitation (lmax = 
R-S-S-R                        2 RSH                                               Equation 2.3.1 
R-S-N=O                        NO + ½ RS-SR                               Equation 2.3.2 
R-S-N=O                         NH2OH + ½ RS-SR                      Equation 2.3.3 
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494nm) or emission (lmax = 520nm) spectrum of fluorescein because of the close 
proximity of the functional group to the fluorophore. 
 
 
Figure 2.3 MM2 energy minimized and 2D structures of A- DTFCys2, B- DTFHCys2, C-TFSNOG and D-
AOASNOG. The black lines indicate intramolecular H-bonds 
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2.4 Materials 
 Glutathione (reduced), Isatoic anhydride, fluorescein isothiocyanate (FITC), 
Cystine, Homocystine, and sephadex G-50 were all purchased from Sigma Aldrich. Silica 
plateTM TLC plates were purchased from SiliCycle Inc.  
2.5 Methods 
2.5.1 N,N-di(thioamido-fluoresceinyl)-cystine (DTFCys2, figure 2.3.1A) 
 L-Cystine (0.1mmol) was dissolved in 3.0mL of 0.1M sodium carbonate solution. 
This was added to a solution of 0.25mmol FITC dissolved in 3.0mL of acetone. This was 
left to react for 24 hours at 50°C protected from light. The reaction mixture was 
lyophilized and applied onto a 2.5cm x 30cm Econo column filled with Sephadex   G-50 
that has been equilibrated with water. DTFCys2 was eluted using 3 column volumes and 
the fraction was concentrated by lyophilization, dissolved in water and divided into 
100mL aliquots for freezing at -20°C. The final product was characterized using NMR, 
UV/Vis, and Fluorescence spectroscopy. The 1H-NMR spectrum was characterized by 
the fluoresceinyl-protons ranging from 5.7 to 7.4ppm, and multiplets corresponding to the 
Cys protons all summarized in Table C1 of appendix C. The UV/Vis spectrum was 
characterized by the large fluoresceinyl-absorbance peak (lmax = 494nm, eM=176,000 M-
1cm-1). There was also a shoulder due to the fluoresceinyl-moieties overlapping at 475nm. 
The absorbance contributions of the S-N=O moiety was buried within the broad aromatic 
contribution from the fluorescein moiety.  
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2.5.2 N,N-di(thioamido-fluoresceinyl)-homocystine (DTFHCys2, figure 2.3.2B) 
The procedure for the synthesis of DTFHCys2 was the same as that used for 
DTFCys2 with 0.1mmol L-Homocystine. The final product was characterized using 
NMR, UV/Vis, and Fluorescence spectroscopy. The 1H-NMR spectrum was like that of 
DTCys2 with the addition of two peaks all summarized in Table C1 of appendix C. The 
UV/Vis spectrum was characterized by the large fluoresceinyl-absorbance peak (lmax = 
494nm, eM=176,000 M-1cm-1). There was also a shoulder due to the fluoresceinyl-
moieties overlapping at 475nm that was seen for DTFCys2.  
 
2.5.3 N-amido-O-aminobenzoyl-S-nitrosoglutathione (AOASNOG, figure 2.3.2D) 
S-nitrosoglutathione was synthesized using Hart’s Method.80 SNOG (0.32mmol) 
and 1.84mmol Isatoic anhydride (recrystallized from isopropanol) which were dissolved 
in 0.5M phosphate buffer pH8 and left to react for 24 hours at 22°C protected from light. 
The reaction mixture was applied to a 1cm x 10cm Econo column packed with 1g of 
QAE-Sephadex equilibrated with water. The column was washed with 50mL of water 
and the AOASNOG was eluted using 0.1M phosphate buffer containing 0.5M NaCl pH 
7.4. The product was concentrated by lyophilization, dissolved in 2.0mL of water and 
divided into aliquots for freezing at -20°C. AOASNOG was characterized using NMR, 
UV/Vis, and Fluorescence spectroscopy. The 1H-NMR spectra of SNOG and 
AOASNOG were compared. The largest chemical shift change observed in the 
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AOASNOG spectrum which indicated the presence of the o-aminobenzoyl group and 
aromatic protons. The NMR results are summarized in Table C2 of appendix C.84 The 
UV/Vis spectrum is characterized by a broad peak that consist of the absorbance of        
o-aminobenzoyl (lmax = 312 nm, eM= 2,800 M-1cm-1) and a shoulder from the -SNO 
group (lmax = 335 nm, eM= 920 M-1cm-1). There was also a small contribution in the red 
range (lmax = 545 nm, eM=16 M-1cm-1) due to the second weaker -SNO absorbance.85 
The fluorescence properties of AOASNOG have previously been detailed, further 
confirming that AOASNOG is weakly fluorescent because of the close spatial and 
overlapping spectra of the excitation spectrum of o-aminobenzoyl-moiety and the             
-S-N=O absorbance. This shows that AOASNOG has the ability to act as a fluorogenic 
reporter of chemical changes to the -S-N=O functionality through the loss of NO+ or the 
reduction of -S-N=O to -S-NHOH by enzymes like S-nitrosoglutathione reductase 
(GSNOR) leading to a 14 fold increase in fluorescence at 412nm.84 
 
2.5.4  N-thioamido-fluoresceinyl-S-nitroso-glutathione (TFSNOG, figure 2.3.2C) 
S-nitrosoglutathione (0.3mmol) was dissolved in 4mL of 0.2M NaHCO3 pH 9. This 
solution was then added to a solution of 0.1mmol FITC dissolved in 4mL of acetone. 
This was left to react for 4 hours at 22°C protected from light. The product was applied to 
a 1.5cm x 10cm Econo column packed with 2mL of Dowex-1 (Cl- form). FITC and GSH 
do not have a strong interaction with the Dowex-1 because at pH 7 they have net charges 
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of -2 and -1, respectively. However, TFSNOG at pH 7 has a net charge of -4 and has a 
strong interaction with the Dowex-1. Isolation of the product was started by washing the 
with 50mL of 0.1M Tris-HCl pH 7.4 and the TFSNOG eluted using the same buffer 
containing 1M NaCl. The eluate was concentrated by lyophilization then re-dissolved in 
0.5mL of water and desalted on a packed column of 15mL Sephadex G-25 equilibrated 
using distilled water. The fraction containing TFSNOG was collected, concentrated by 
lyophilization, and divided into aliquots for freezing at -20°C.  
TFSNOG was characterized using NMR, UV/Vis, and Fluorescence spectroscopy. 
The 1H-NMR spectra of TFSNOG showed a range of 6.3ppm to 7.6ppm for the aromatic 
protons of the fluoresceinyl-moiety and peaks for multiplets corresponding to the proton 
of Glu and Gly of SNOG all summarized in Table C1 of appendix C. UV/Vis spectrum of 
TFSNOG showed a large absorbance peak for the fluoresceinyl-moiety (lmax = 494 nm, 
eM=88,000 M-1cm-1) with the contribution from the -SNO moiety buried within the broad 
peak. TFSNOG has a low fluorescence because of the overlap between the -S-N=O 
absorbance, lmax = 545nm and the fluoresceinyl-emission, lmax = 520 nm. The 
fluorescence increases upon denitrosylation with DTT. 
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2.6 Results 
  
Figure 2.6 A: UV/Vis spectrum of DTFCys2 (red dash line), DTFHCys2 (blue dash line) and 
TFSNOG (black dash line); B: Fluorescence emission spectrum of TFSNOG before (dash 
line) and after the addition of DTT (50µM, red line); C: Fluorescence emission spectrum of 
DTFCys2 before (red dash) and after the addition of DTT (50µM, red line). Fluorescence 
emission spectrum of DTFHCys2 before (blue dash) and after the addition of DTT (50µM, 
blue line). 
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2.6.1 Free thiol determination 
DTFCys2 and DTFHCys2 can be used as fluorescent reagents for detecting free thiol 
concentration just like Ellman’s reagent86 via the thiol disulfide exchange shown in 
Equation 2.6.1. This reagent can be used to determine nmol levels of free thiols (Figure 
2.6.1). 
F-Cys-S-S-Cys-F + RS- ® R-S-S-Cys-F + F-Cys-S-          Equation 2.6.1 
  low fluorescence        higher fluorescence 
   
Figure 2.6.1 Constant volume of DTFCys2 (A) and DTFHCys2 (B) were added to 
the first 9 wells of a 96-well plate. The first two well were used as control and to 
wells 4-6 increasing amounts of DTT (blue) were added. Wells 7-9 had increasing 
amounts of GSH (red). Each point accounts for the increase in thiol concentration. 
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2.6.2 Kinetic Characterization of disulfide reductases in vitro and in live cells 
Researchers had shown that cells have a cell surface associated form of PDI.87-97 
DTFCys2 can also be used to kinetically characterize pure recombinant PDI and cell 
surface PDI of ARPE cells. These reagents can also be used in imaging cell surface thiols 
from PDI to other free protein thiols on live cells. Figure 2.6.2b shows ARPE cells 
exposed to DTFCys2. 
 
  
Figure 2.6.2a; A: constant volume of purified recombinant PDI was added to 96-well plates 
with increasing amounts of DTFCys2 and enzymatic reaction was initiated by the addition of 
DTT. B: ARPE cells grown to confluence in wells of a 96-well plate had increasing amounts 
of DTFCys2 added to it the wells and change in fluorescence was monitored at 520nm for 9 
minutes. The fit used to estimate the value of KM is showed as the red dashed line. 
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Figure 2.6.2b ARPE cells grown at the bottom of 96-well plates exposed to PBS (control)- panel A, B, C 
and DTFCys2- Panel D, E, F for 15 mins. imaged from the bottom of the plate using an inverted 
epifluorescence microscope (Zeiss Axiovert 200) equipped with an FITC cube. Overlay of the DIC images 
of the cells done with the aid of Corel paint shop pro 2018. 
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2.6.3 Kinetic characterization of S-nitrosoglutathione reductase in vitro and live cells 
AOASNOG is currently the only cell permeable, pseudo-substrate for S-
nitrosoglutathione reductase.84 This section demonstrates how it can be used to 
kinetically characterize ARPE cells (Figure 2.6.3B). TFSNOG the fluorescein analog of 
AOASNOG acts as a pseudo-substrate for the S-denitrosylation activity of PDI.98   
Figure 2.6.3 A: constant volume of purified PDI with increasing amounts of TFSNOG were added to the 
wells of a 96-well plate and enzymatic activity was initiated by the addition of DTT. B: ARPE cells grown 
to confluence in wells of a clear 96-well plate had increasing amounts of AOASNOG added to the wells. 
Changes in fluorescence was monitored at 520nm (A) and 412 (B) every 35s for 9 minutes.  
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2.7 Discussion 
The purpose of this study was to describe the theoretical basis and simple methods 
for synthesizing four probes/reagents that can be used in various applications such as the 
measuring and imaging of free thiols on cell surface as well as how they can perform as 
pseudo-substrates for monitoring enzymatic activities. Each reagent was characterized 
using NMR as well as UV/Vis and Fluorescence spectroscopy. Thin Layer 
Chromatography (TLC) was performed using SiliaPlate TLC aluminum backed plates 
with varying mobile phases that provided the best separation. The mobile phase used for 
DTFCys2, DTFHCys2, and TFSNOG was acetone:water:methanol in a 10:10:1 ratio.  For 
AOASNOG the mobile phase composition was acetone:water:methanol in a 13:6:1 ratio. 
The multiple spots observed for FITC are due to the different prototrophic forms of 
fluorescein.107  
The disulfide-linked probes DTFCys2 and DTFHCys2 can function as fluorescent 
reagents for the detection of free thiol concentrations just like the classical colorimetric 
thiol reagent 5,5’-dithiobis-2-nitrobenzoate (Ellman’s reagent) from the thiol disulfide 
exchange. However, unlike the Ellman’s reagent, the fluorescence signal from these new 
regents enables the detection of thiol concentrations in the nmol levels. DTFCys2 can be 
used to kinetically characterize recombinant PDI and cell surface PDI of ARPE in culture 
with estimated KM for the PDI mediated disulfide reduction which was ~1.9µM and was 
close to the estimated KM for the ARPE-surface PDI of 2.72µM. the Michaelis Menten 
equation was used to estimate the steady-state kinetic parameters from a fit of the data. A 
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KM of 740µM was estimated for AOASNOG in the ARPE-GSNOR catalyzed 
denitrosation which comes close to the KM for recombinant GSNOR of 320µM. TFSNOG 
functions as a pseudo-substrate for the S-denitrosylase activity of PDI with an estimated 
KM of 11.1µM that corresponds to a higher affinity of about 6-fold compared to that of 
SNOG (65µM). Unfortunately, TFSNOG was not a pseudo-substrate for GSNOR. Apart 
from the large applications to enzymology and cell biology, the reagents cost less to 
produce because the fluorescein isothiocyanate is less expensive than eosin 
isothiocyanate for example. In addition, fluorescein derivatives are much easier to purify.  
 
2.8 Conclusion 
 The reagents outlined here are easy to prepare and purify. They can be used in 
diverse applications ranging from their use as thiol reagents to pseudo-substrates for 
monitoring enzymatic activities in vitro.  
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APPENDIX A – Recombinant GSNOR 
 
 
 
Figure A.1: Recombinant wild type GSNOR protein 
sequence. Amino acids are numbered from Met1 to Ile374, 
excluding the added histidine-tag (italicized). 
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Figure A.2: Recombinant GSNOR Plasmid Map. 
 
The following was designed and performed by Dr Bei Sun.5 Human ADH5 was 
purchased from Origene (SC119755) and sub-cloned into the bacterial expression 
vector pET28b using Cold Fusion Cloning Kit (MJS BioLynx Inc. SYMC010A1). 
The following primers for PCR were designed according to manufacturer’s 
guidelines: 
Forward 5’ –GTGCCGCGCGGCAGCCATATGGCGAACGAGGTTATCAAG– 3’ 
Reverse 5’ –GTGGTGGTGGTGGTGCTCGAGAATCTTTACAACAGTTCGAATG– 3’ 
Colonies were screened using diagnostic restriction enzyme digest and by 
partial sequencing (Robarts Research Institute, London Regional Genomics 
Center, London, Ontario, Canada). The final recombinant GSNOR contains a 6X-
histidine tag at each terminus. 
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APPENDIX B – Mass Spectrometry to identify peptides of GSNOR 79 
  1 10 20 
MGSSHHHHHH SSGLVPRGSH MANEVIKCKA AVAWEAGKPL 
30 40 50 60 
SIEEIEVAPP KAHEVRIKIIA TAVCHTDAY TLSGADPEGC 
70 80 90 100 
FPVILGHEGA GIVESVGEGV TKLKAGDTVI PLYIPQCGEC 
110 120 130 140 
KFCLNPKTNL CQKIRVTQGK GLMPDGTSRF TCKGKTILHY 
150 160 170 180 
MGTSTFSEYT VVADISVAKI DPLAPLDKVC LLGCGISTGY 
190 200 210 220 
GAAVNTAKLE PGSVCAVFGL GGVGLAVIMG CKVAGASRII 
230 240 250 260 
GVDINKDKFA RAKEFGATEC INPQDFSKPI QEVLIEMTDG 
270 280 290 300 
GVDYSFECIG NVKVMRAALE ACHKGWGVSV VVGVAASGEE 
310 320 330 340 
IATRPFQLVT GRTWKGTAFG GWKSVESVPK LVSEYMSKKI 
250 360 370 374 
KVDEFVTHNL SFDEINKAFE LMHSGKSIRT VVKI 
LEHHHHHH    
 
Figure B.1 GSNOR Peptide Map 
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Table B.1: Full peptide list resulting from MS-MS identification. Theoretical amino 
acid number corresponds to labels beginning at Met1, whereas experimental amino acid 
numbers include the His tags of the recombinant protein. 292 total amino acids have been 
sequenced, however only 188 unique amino acids have coverage, resulting in a 52% 
sequence coverage of the 374 relevant residues. 48% coverage with His tags included. 
 
m/
z 
Theoretical 
Amino Acid 
Number 
Experimental 
Amino Acid 
Number 
 
Amino Acid Sequence 
813.3543 0-6 20-26 (S)HMANEVI(K) 
690.0621 7-11 27-33 (I)KCKAAVA/(W) 
621.4647 11-22 31-42 (A)/AVAWEAGKPLSI(E) 
545.9043 25-43 45-54 (E)/IEVAPPKAHE/(V) 
406.9651 35-41 55-61 (E)/VRIKIIA/(T) 
457.5103 35-42 55-62 (E)/VRIKIIAT(A) 
508.7969 42-56 62-76 (A)/TAVCHTDAYTLSGAD(P) 
462.4796 52-56 72-76 (T)LSGAD(P) 
762.2355 64-79 84-99 (V)ILGHEGAGIVESVGEG(V) 
749.1952 66-81 86-101 (L)/GHEGAGIVESVGEGVT(K) 
1260.826 75-87 95-107 (E)/SVGEGVTKLKAGD(T) 
1017.545 78-87 98-107 (G)EGVTKLKAGD(T) 
889.3751 91-98 111-118 (I)PLYIPQCG(E) 
863.8682 131-138 151-158 (F)/TCKGKTIL/(H) 
796.6921 139-145 159-165 (L)/HYMGTST(F) 
903.3278 187-195 207-215 (T)AKLEPGSVC(A) 
646.5185 190-203 210-223 (L)/EPGSVCAVFGLGGV(G) 
1091.721 194-205 214-225 (S)VCAVFGLGGVGL/(A) 
1074.582 210-220 230-240 (M)GCKVAGASRII(G) 
537.7998 211-221 231-241 (G)CKVAGASRIIG(V) 
950.457 223-230 243-250 (V)DINKDKFA/(R) 
1053.654 228-236 248-256 (D)KFARAKEFG(A) 
669.6493 231-242 251-262 (A)/RAKEFGATECIN(P) 
726.2026 233-246 253-265 (A)/KEFGATECINPQD(F) 
818.1564 239-245 259-265 (T)ECINPQD(F) 
1061.054 246-254 266-274 (D)FSKPIQEVL/(I) 
1038.94 315-324 335-344 (W)/KGTAFGGWKS(V) 
1173.876 320-330 340-350 (F)/GGWKSVESVPK(L) 
587.3912 324-334 344-354 (K)SVESVPKLVSE/(Y) 
1241.154 334-343 354-363 (S)EYMSKKIKVD(E) 
965.4494 353-360 373-380 (F)/DEINKAFE/(L) 
1231.957 354-363 374-383 (D)EINKAFELMH(S) 
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APPENDIX C – Supplementary Data for the development of pseudo-substrate 111 
Table C1: 1H-NMR chemical shifts for the outlined reagents 
Reagents Chemical Shifts (ppm) 
TFSNOG (500 MHz, D20, d) 2.06 (*m, 2H, Glu, Hb) 
 2.42 (t, 2H, Glu, Hg) 
 3.69 (b, 1H, Glu, Ha) 
 3.96 (s, 1H, Gly, Ha) 
 4.00 (b, 1H, Cys, Hb) 
 6.73-7.75 (aromatic H of fluoresceinyl protons)  
TFHCys2 (500 MHz, D20, d) 2.29 (m, 1H, HCys, Ha) 
 2.73 (m, 2H, HCys, Hb) 
 3.58 (t, 2H, HCys, Hg) 
 6.32-7.57 (aromatic H of fluoresceinyl protons)  
TFC2Cys2 (500 MHz, D20, d) 2.51 (t, 2H, Cys, Hb) 
 3.03 (q, 2H, Cys, Hb) 
 3.78 (t, 1H, Cys, Ha) 
 6.46-7.75 (aromatic H of fluoresceinyl protons) 
  
  
*Abbreviations: δ, chemical shift in parts per million (ppm) downfield from the standard Multiplicities: s, singlet; t, 
triplet; q, quartet; m, multiplet; b, broadened. 
  
 
 
 
 
 
79 
Table C2: 1H-NMR chemical shift for GSNO and AOASNOG (OAbz-GSNO) 
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Figure C1: TLC of starting materials and the products, after purification, visualized by UV lamp (254 nm- 
plates A, B, C; 366 nm plate D) or I2 vapor. A- DTFCys2, B- DTFHCys2, C-TFSNOG, D-AOASNOG. 
Multiple bands observed in FITC are due to prototropic forms of fluorescein (ref 13 in paper). The mobile 
phase employed for DTFCys2, DTFHCys2, and TFSNOG was acetone: water: methanol in a 10:10:1. For 
AOASNOG the mobile phase composition was acetone: water: methanol in a 13:6:1 
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